1. Ranke M.B. The KIGS etiology classification system. In: Growth hormone therapy in KIGS - 10 etars' experience. Ed. M.B. Ranke, P. Wilton. Heideberg; Leipzig: Barth, 1999; 389 - 401.

2. Cogan J.D., Phillips 3rd J.A. Growth disorders caused by genetic defects in the growth hormone pathway. Adv Pediatr. 1998; 45: 337 - 361.

3. Wagner J.K., A., Hindmarsh P.C., Mullis P.E. Prevalence of human GH-1 gene alterations in patients with isolated growth hormone deficiency. Pediatr Res. 1998; 43(1): 105 - 10.

4. Cogan J.D., Phillips 3rd J.A., Sakati N., et al. Heterogeneous growth hormone (GH) gene mutations in familial GH deficiency. J Clin Endocrinol Metab. 1993; 76(5): 1224 - 1228.

5. Ryther R.C.C., McGuinness L.M., Phillips 3rd J.A., et al. Disruption of exon definition produces a dominant-negative growth hormone isoform that causes somatotroph death and IGHD II. Hum Genet. 2003; 113(2): 140 - 148.

6. Fofanova O.V., Evgrafov O.V., Polyakov A.V., et al. A novel IVS2 - 2A > T splicing mutation in the GH-1 gene in familial isolated growth hormone deficiency type II in the spectrum of other splicing mutations in the Russian population. J Clin Endocrinol Metab. 2003; 88(2): 820 - 826.

7. Petkovic V., Lochmatter D., Turton J., et al. Exon splice enhancer mutation (GH-E32A) causes autosomal dominant growth hormone deficiency. J Clin Endocrinol Metab. 2007; 92(11): 4427 - 4435.

8. Wajnrajch M.P., Gertner J.M., Harbison M.D., et al. Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse. Nat Genet. 1996; 12(1): 88 - 90.

9. Frohman L.A., Kineman R.D. Growth hormone-releasing hormone and pituitary somatotrope proliferation. Minerva Endocrinol. 2002; 27(4): 277 - 285

10. Xatzipsalti M., Voutetakis A., Stamoyannou L., et al. Congenital hypopituitarism: various genes, various phenotypes. Horm Metab Res. 2019; 51(2): 81 - 90.

11. Ohta K., Nobukuni Y., Mitsubuchi H., et al. Mutations in the Pit-1 gene in children with combined pituitary hormone deficiency. Biochem Biophys Res Commun. 1992; 189(2): 851 - 855.

12. Fofanova O.V., akamura N., Kinoshita E., et al. Rarity of PIT1 involvement in children from Russia with combined pituitary hormone deficiency. Am J Med Genet. 1998; 77(5): 360 - 5.

13. Wu W., Cogan J.D., Pfaffle R.W., Dasen J.S., et al. Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet. 1998; 18(2): 147 - 149.

14. Birla S., Khadgawat R., Jyotsna V.P., et al. Identification of novel PROP1 and POU1F1 mutations in patients with combined pituitary hormone deficiency. Horm Metab Res. 2016 Dec; 48(12): 822 - 827.

15. Penta L., Bizzarri C., Panichi M., et al. Identification of a novel PROP1 mutation in a patient with combined pituitary hormone deficiency and enlarged pituitary. Int J Mol Sci. 2019; 20(8): 1875.

16. McNay D.E.G., Turton J.P., Kelberman D., et al. HESX1 mutations are an uncommon cause of septooptic dysplasia and hypopituitarism. J Clin Endocrinol Metab. 2007; 92(2): 691 - 697.

17. Cohen L.E., Wondisford F.E., Radovick S. Role of Pit-1 in the gene expression of growth hormone, prolactin, and thyrotropin. Endocrinol Metab Clin North Am. 1996; 25(3): 523 - 540.

18. Гаврилова А.Е., Нагаева Е.В., Ширяева Т.Ю., Тюльпаков А.Н, Петеркова В.А. Новая гетерозиготная мутация гена POU1F1, ассоциированная с множественным дефицитом гормонов аденогипофиза. Проблемы эндокринологии. 2017; 63(3): 166 - 169.

19. Vieira T.C., Boldarine V.T., Abucham J. Molecular analysis of PROP1, PIT1, HESX1, LHX3, and LHX4 shows high frequency of PROP1 mutations in patients with familial forms of combined pituitary hormone deficiency. Arq Bras Endocrinol Metabol. 2007; 51(7): 1097 - 1103.

20. Agarwal G., Bhatia V., Cook S., Thomas P.Q.J. Adrenocorticotropin deficiency in combined pituitary hormone deficiency patients homozygous for a novel PROP1 deletion. Clin Endocrinol Metab. 2000; 85(12): 4556 - 4561.

21. A., Keller E., Kratzsch J., et al. PROP1 mutations cause progressive deterioration of anterior pituitary function including adrenal insufficiency: a longitudinal analysis. J Clin Endocrinol Metab. 2004; 89(10): 5256 - 5265.

22. Riepe FG, Partsch CJ, Blankenstein O, et al. Longitudinal imaging reveals pituitary enlargement preceding hypoplasia in two brothers with combined pituitary hormone deficiency attributable to PROP1 mutation. J Clin Endocrinol Metab. 2001; 86: 4353 - 4357.

23. Voutetakis A, Argyropoulou M, Sertedaki A, et al. Pituitary magnetic resonance imaging in 15 patients with PROP1 gene mutations: pituitary enlargement may originate from the intermediate lobe. J Clin Endocrinol Metab. 2004; 89: 2200 - 2206.

24. BB, MG, Latronico AC, et al. Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301, G302 in the PROP1 gene. J Clin Endocrinol Metab. 1999; 84: 942 - 945.

25. do Amaral L.L.F., Ferreira R.M., Ferreira N.P.F.D., et al. Combined pituitary hormone deficiency and PROP-1 mutation in two siblings: a distinct MR imaging pattern of pituitary enlargement. AJNR Am J Neuroradiol. 2007; 28(7): 1369 - 1370.

26. Nolen L.D., Amor D., Haywood A., et al. Deletion at 14q22-23 indicates a contiguous gene syndrome comprising anophthalmia, pituitary hypoplasia, and ear anomalies. Am J Med Genet A. 2006; 140(16): 1711 - 1718.

27. Tajima T., Ohtake A., Hoshino M., et al. OTX2 loss of function mutation causes anophthalmia and combined pituitary hormone deficiency with a small anterior and ectopic posterior pituitary. J Clin Endocrinol Metab. 2009; 94(1): 314 - 319.

28. Diaczok D., Romero C., Zunich J., et al. A novel dominant negative mutation of OTX2 associated with combined pituitary hormone deficiency. J Clin Endocrinol Metab. 2008; 93(11): 4351 - 4359.

29. Shimada A., Takagi M., Nagashima Y., et al. A novel mutation in OTX2 causes combined pituitary hormone deficiency, bilateral microphthalmia, and agenesis of the left internal carotid artery. Horm Res Paediatr. 2016; 86(1): 62 - 69.

30. Roessler E., Du Y.Z., Mullor J.L., et al. Loss-of-function mutations in the human GLI2 gene are associated with pituitary anomalies and holoprosencephaly-like features. Proc Natl Acad Sci USA. 2003; 100(23): 13424 - 13429.

31. Kevelam S.H., van Harssel J.J., van der Zwaag B., et al. A patient with a mild holoprosencephaly spectrum phenotype and heterotaxy and a 1.3 Mb deletion encompassing GLI2. Am J Med Genet A. 2012; 158A(1): 166 - 173.

32. M.M., Jorge A.A.L., Carvalho L.R.S., et al. Novel heterozygous nonsense GLI2 mutations in patients with hypopituitarism and ectopic posterior pituitary lobe without holoprosencephaly. 2010; 95(11): E384 - 391.

33. Demiral M., Demirbilek H., Unal E., et al. Ectopic posterior pituitary, polydactyly, midfacial hypoplasia and multiple pituitary hormone deficiency due to a novel heterozygous IVS11 - 2A > C c. 1957 - 2A > C) mutation in the GLI2 gene. J Clin Res Pediatr Endocrinol. 2020; 12(3): 319 - 328.

34. Ramzan K., Bin-Abbas B., Al-Jomaa L., et al. Two novel LHX3 mutations in patients with combined pituitary hormone deficiency including cervical rigidity and sensorineural hearing loss. BMC Endocr Disord. 2017; 17(1): 17.

35. Pfaeffle R.W., Savage J.J., Hunter C.S., et al. Four novel mutations of the LHX3 gene cause combined pituitary hormone deficiencies with or without limited neck rotation. J Clin Endocrinol Metab. 2007; 92(5): 1909 - 1919.

36. Machinis K., Pantel J., Netchine I., et al. Syndromic short stature in patients with a germline mutation in the LIM homeobox LHX4. Am J Hum Genet. 2001; 69(5): 961 - 968.

37. Castinetti F., Saveanu A., Reynaud R., et al. A novel dysfunctional LHX4 mutation with high phenotypical variability in patients with hypopituitarism. J Clin Endocrinol Metab. 2008; 93(7): 2790 - 2799.

38. Дедов И.И., Петеркова В.А. Руководство по детской эндокринологии. - М.: Универсум Паблишинг, 2006. С. 46 - 89.

39. Bogusz A., H.L. Childhood-onset craniopharyngioma: latest insights into pathology, diagnostics, treatment, and follow-up. Expert Rev Neurother. 2018; 18(10): 793 - 806.

40. Мазеркина Н.А., Коновалов А.Н., Горелышев С.К., и др. Эндокринные нарушения при краниофарингиомах у детей: зависимость от локализации опухоли. Журнал вопросы нейрохирургии им. акад. Н.Н. Бурденко. 2008; (1): 23 - 29.

41. de Vries L., Lazar L., Phillip M. Craniopharyngioma: presentation and endocrine sequelae in 36 children. J Pediatr Endocrinol Metab. 2003; 16(5): 703 - 710.

42. Валиахметова Э.Ф., Быданов О.И., Горелышев С.К., и др. Глиомы зрительного пути у детей: прогностические факторы, оценка ответа и роль двухкомпонентной химиотерапии. Вопросы гематологии, онкологии и иммунопатологии в педиатрии. 2019; 18(1): 62 - 72.

43. Мазеркина Н.А., Горелышев С.К., А.Г. Меликян А.Г., и др. Эндокринные нарушения у детей с медуллобластомой после комбинированного и комплексного лечения. Проблемы эндокринологии. 2008; (2): 35 - 42.

44. Нагаева Е.В., Ширяева Т.Ю., Петеркова В.А., и др. Распространенность и заболеваемость гипофизарным нанизмом в Российской Федерации в 2018 г. Проблемы эндокринологии. 2018; 65(1S): 52 - 61.

45. Lagrou K., Xhrouet-Heinrichs D., G Massa G., et al. Quality of life and retrospective perception of the effect of growth hormone treatment in adult patients with childhood growth hormone deficiency. J Pediatr Endocrinol Metab. 2001; 14 (Suppl 5): 12491260.

46. Webb S.M. Measurements of quality of life in patients with growth hormone deficiency. J Endocrinol Invest. 2008; 31 (9 Suppl): 52 - 55.

47. Sommer G., Gianinazzi M.E., Kuonen R., et al. Health-Related Quality of Life of Young Adults Treated with Recombinant Human Growth Hormone during Childhood. PLoS One. 2015; 10(10): e0140944.

48. Нагаева Е.В., Ширяева Т.Ю., Петеркова В.А., Безлепкина О.Б., Тюльпаков А.Н., Стребкова Н.А., Кияев А.В., Петряйкина Е.Е., Башнина Е.Б., Малиевский О.А., Таранушенко Т.Е., Кострова И.Б., Шапкина Л.А., Дедов И.И. Российский национальный консенсус. Диагностика и лечение гипопитуитаризма у детей и подростков. Проблемы эндокринологии. 2018; 64(6): 402 - 411.

49. Нагаева Е.В. Федеральные клинические рекомендации по диагностике и лечению гипопитуитаризма у детей и подростков. Проблемы эндокринологии. 2013; 59(6): 27 - 43.

50. Guidelines for growth hormone and Insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016; 86: 361 - 397.

51. Kazlauskaite R., Maghnie M. Pitfalls in the diagnosis of central adrenal insufficiency in 872 children. Endocr Dev. 2010; 17: 96 - 107.

52. Patti G., Guzzeti C., Di Iorgi N., et al. Central adrenal insufficiency in children and adolescents. Best Pract Res Clin Endocrinol Metab. 2018; 32(4): 425 - 444.

53. Boehm U., Bouloux P.-M., Mehul T., Dattani M.T., et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism - pathogenesis, diagnosis and treatment. Nature Reviews. Endocrinology. 2015; 11(9): 547 - 564.

54. Grinspon R.P., Ropelato M.G., Silvia Gottlieb S., et al. Basal follicle-stimulating hormone and peak gonadotropin levels after gonadotropin-releasing hormone infusion show high diagnostic accuracy in boys with suspicion of hypogonadotropic hypogonadism. The Journal of Clinical Endocrinology and Metabolism. 2010; 95(6): 2811 - 2818.

55. Harrington J., Palmert M. R. Clinical review: Distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism: critical appraisal of available diagnostic tests. The Journal of Clinical Endocrinology and Metabolism. 2012; 97(9): 3056 - 3067.

56. Odink R.J. Schoemaker J., Schoute E., et al. Predictive value of serum follicle-stimulating hormone levels in the differentiation between hypogonadotropic hypogonadism and constitutional delay of puberty. Hormone Research. 1998; 49(6): 279 - 287.

57. Sequera A.M., Fideleff H.L., Boquete H.R., et al. Basal ultrasensitive LH assay: a useful tool in the early diagnosis of male pubertal delay? Journal of pediatric endocrinology and metabolism: JPEM. 2002; 15(5): 589 - 596.

58. Varimo T., Miettinen P.J., J., et al. Congenital hypogonadotropic hypogonadism, functional hypogonadotropism or constitutional delay of growth and puberty? An analysis of a large patient series from a single tertiary center. Human Reproduction (Oxford, England). 2017; 32(1): 147 - 153.

59. Sun Q.-H., Zheng Yu., Zhang X.-L., et al. Role of gonadotropin-releasing hormone stimulation test in diagnosing gonadotropin deficiency in both males and females with delayed puberty. Chinese Medical Journal. 2015; 128(18): 2439 - 2443.

60. Adan L., Lechevalier P., Couto-Silva A.-C., et al. Plasma inhibin B and hormone concentrations in boys: discriminating between congenital hypogonadotropic hypogonadism and constitutional pubertal delay. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2010; 16(11): CR511 - 517.

61. Coutant R., Biette-Demeneix E., Bouvattier C., et al. Baseline inhibin B and anti-Mullerian hormone measurements for diagnosis of hypogonadotropic hypogonadism (HH) in boys with delayed puberty. The Journal of Clinical Endocrinology and Metabolism. 2010; 95(12): 5225 - 5232.

62. Gao Y., Du Q., Liu L., et al. Serum inhibin B for differentiating between congenital hypogonadotropic hypogonadism and constitutional delay of growth and puberty: a systematic review and meta-analysis. Endocrine. 2021; 72(3): 633 - 643.

63. Bang A.K., Nordkap L., Almstrup K., et al. Dynamic GnRH and hCG testing: establishment of new diagnostic reference levels. European Journal of Endocrinology. 2017; 176(4): 379 - 391.

64. Smals A.G., Hermus A.R., Boers G.H., et al. Predictive value of luteinizing hormone releasing hormone (LHRH) bolus testing before and after 36-hour pulsatile LHRH administration in the differential diagnosis of constitutional delay of puberty and male hypogonadotropic hypogonadism. The Journal of Clinical Endocrinology and Metabolism. 1994; 78(3): 602 - 608.

65. Wilson D.A., Hofman P.L., Miles H.L., et al. Evaluation of the buserelin stimulation test in diagnosing gonadotropin deficiency in males with delayed puberty. The Journal of Pediatrics. 2006; 148(1): 89 - 94.

66. Patti G., Ibba A., Morana G., et al. Central diabetes insipidus in children: Diagnosis and management. Best Pract Res Clin Endocrinol Metab. 2020; 34(5): 101440.

67. Fenske W, Allolio B. Current state and future perspectives in the diagnosis of diabetes insipidus: A clinical review. J Clin Endocrinol Metab. 2012; 97(10): 3426 - 3437.

68. Gubbi S., Hannah-Shmouni F., Koch C.A., et al. Diagnostic testing for diabetes insipidus. Endotext 2000. https://www.ncbi.nlm.nih.gov/books/NBK537591/#diagn-diabet-insip.REFERENCES

69. de Fost M., Oussaada S.M., Endert E., et al. The water deprivation test and a potential role for the arginine vasopressin precursor copeptin to differentiate diabetes insipidus from primary polydipsia. Endocr. Connect. Endocr Connect, 2015; 4(2): 86 - 91.

70. Pedrosa W., Drummond J.B., Soares B.S., et al. A combined outpatient and inpatient overnight water deprivation test is effective and safe in diagnosing patients with polyuria-polydipsia syndrome. Endocr. Pract. Endocr Pract. 2018; 24(11): 963 - 972.

71. Iorgi N.D., Morana G., Napoli F., et al. Management of diabetes insipidus and adipsia in the child. Best Pract Res Clin Endocrinol Metab. 2015; 29(3): 415 - 436.

72. Fenske W., Quinkler M., Lorenz D., et al. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome-revisiting the direct and indirect water deprivation tests. J. Clin. Endocrinol. Metab. J Clin Endocrinol Metab. 2011; 96(5): 1506 - 1515.

73. Fenske W., Refardt J., Chifu I., et al. A copeptin-based approach in the diagnosis of diabetes insipidus. N Engl J Med. 2018; 379(5): 428 - 439.

74. Winzeler B., Cesana-Nigro N., Refardt J., et al. Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. Lancet. 2019; 394 (10198): 587 - 595.

75. Sailer C.O., Julie Refardt J., Claudine Angela Blum C.A, et al. Validity of different copeptin assays in the differential diagnosis of the polyuria-polydipsia syndrome. Sci Rep. 2021; 11(1): 10104.

76. L., Souberbielle J.C., Pinto G., et al. The use of insulin-like growth factor 1 reference values for the diagnosis of growth hormone deficiency in prepubertal children. Clin Endocrinol (Oxf). 2000; 52(6): 735 - 739.

77. Ibba A., Corrias F., Guzzetti C., et al. Endocr Connect. IGF1 for the diagnosis of growth hormone deficiency in children and adolescents: a reappraisal. 2020; 9(11): 1095 - 1102.

78. Inoue-Lima T.H., Vasques G.A., Nakaguma M., et al. A bayesian approach to diagnose growth hormone deficiency in children: insulin-like growth factor type 1 is valuable for screening and IGF-binding protein type 3 for confirmation. Horm Res Paediatr. 2020; 93(3): 197 - 205.

79. Inoue-Lima T.H., Vasques G.A., Scalco R.C., et al. IGF-1 assessed by pubertal status has the best positive predictive power for GH deficiency diagnosis in peripubertal children. J Pediatr Endocrinol Metab. 2019; 32(2): 173 - 179.

80. Wang Y., Zhang H., Cao M., et al. Analysis of the value and correlation of IGF-1 with GH and IGFBP-3 in the diagnosis of dwarfism. Exp Ther Med. 2019; 17(5): 3689 - 3693.

81. Ali A., Hashim R., Khan F.A., et al. Evaluation of insulin-like growth factor-1 and insulin like growth factor binding protein-3 in diagnosis of growth hormone deficiency in short-stature children. J Ayub Med Coll Abbottabad. 2009; 21(3): 40 - 45.

82. J.S., L.C., Moraes M.A., et al. Diagnosis of idiopathic GHD in children based on response to rhGH treatment: the importance of GH provocative tests and IGF-1. Front Endocrinol (Lausanne). 2019; 19(10): 638.

83. Lee N.Y., Kim S.E., Kim S., et al. Effect of body mass index on peak growth hormone level after growth hormone stimulation test in children with short stature. Ann Pediatr Endocrinol Metab. 2021; 26(3): 192 - 198.

84. Yang A., Cho S.Y., Kwak M.J., et al. Impact of BMI on peak growth hormone responses to provocative tests and therapeutic outcome in children with growth hormone deficiency. Sci Rep. 2019; 9(1): 16181

85. Yackobovitch-Gavan M., Lazar L., Diamant R., et al. Diagnosis of growth hormone deficiency in children: the efficacy of glucagon versus clonidine stimulation test. Horm Res Paediatr. 2020; 93(7 - 8): 470 - 476.

86. Saggese G., Cesaretti G., Giannessi N., et al. Stimulated Growth hormone (GH) secretion in children with delays in pubertal development before and after the onset of puberty: relationship with peripheral plasma GH-releasing hormone and somatostatin levels. J Clin Endocrinol Metab. 1992; 74(2): 272 - 278.

87. Martinez A.S., Domene H.M., Ropelato M.G., et al. Estrogen priming effect on growth hormone (GH) provocative test: a useful tool for the diagnosis of GH deficiency. J Clin Endocrinol Metab. 2000; 85(11): 4168 - 4172.

88. Marin G., Domene Hm., Barnes Km., et al. The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J Clin Endocrinol Metab. 1994; 79(2): 537 - 541.

89. Zadik Z. Sex steroid priming for growth hormone (GH) provocative tests: an endless debate with insufficient solutions. J Pediatr Endocrinol Metab. 2011; 24(1 - 2): 3 - 4.

90. De Sanctis V., Soliman A.T., Yassin M., et al. Is priming with sex steroids useful for defining patients who will benefit from GH treatment? Pediatr Endocrinol Rev. 2014; 11(3): 284 - 287.

91. Gone E.N., Kandemir N., Ozon A., Alikasifoglu A. Final heights of boys with normal growth hormone responses to provocative tests following priming. J Pediatr Endocrinol Metab. 2008; 21(10): 963 - 971.

92. Kelly A., Tang R., Becker S., Stanley C.A. Poor specificity of low growth hormone and cortisol levels during fasting hypoglycemia for the diagnoses of growth hormone deficiency and adrenal insufficiency. Pediatrics. 2008; 122(3): E522 - E528.

93. Loche S., Bizzarri C., Maghnie M., et al. Results of early reevaluation of growth hormone secretion in short children with apparent growth hormone deficiency. J Pediatr. 2002; 140(4): 445 - 449.

94. Secco A., Di Iorgi N., Napoli F., et al. Reassessment of the growth hormone status in young adults with childhood-onset growth hormone deficiency: reappraisal of insulin tolerance testing. J Clin Endocrinol Metab. 2009; 94(11): 4195 - 4204.

95. Maghnie M., Aimaretti G., Bellone S., et al. Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. Eur J Endocrinol. 2005; 152(4): 589 - 596.

96. Quigley C.A., Zagar A.J., Liu C.C., et al. United States multicenter study of factors predicting the persistence of GH deficiency during the transition period between childhood and adulthood. Int J Pediatr Endocrinol. 2013; 2013(1): 6.

97. Maghnie M., Strigazzi C., Tinelli C., et al. Growth hormone (GH) deficiency (GHD) of childhood onset: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults. J Clin Endocrinol Metab. 1999; 84(4): 1324 - 1328.

98. Hartman M.L., Crowe B.J., Biller B.M., et al. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab. 2002; 87(2): 477 - 485.

99. Attanasio A.F., Howell S., Bates P.C., et al. Confirmation of severe GH deficiency after final height in patients diagnosed as GH deficient during childhood. Clin Endocrinol (Oxf). 2002; 56(4): 503 - 507.

100. Cavarzere P., Gaudino R., Sandri M., et al. Growth hormone retesting during puberty: a cohort study. Eur J Endocrinol. 2020; 182(6): 559 - 567.

101. Banerjee I., Tudorancea A., Scanlon M.F., Gregory J.W. Are factors at diagnosis of growth hormone deficiency in childhood associated with persistence of growth hormone deficiency into adult life? J Pediatr Endocrinol Metab. 2005; 18(10): 943 - 947.

102. Greulich W., Pyle I. Radiographic atlas of skeletal development of the hand and wrist. London: Stanford University Press; 1959.

103. Tanner J.M., Cameron N., Marshall W.A., et al. Assessment of skeletal maturity and prediction of adult height. (TW 2 method). London: Academic Press; 1983.

104. Cavallo F., Mohn A., Francesco Chiarelli F., et al. Evaluation of bone age in children: a mini-review. Front Pediatr. 2021; 9: 580314.

105. Prokop-Piotrkowska M., K., E., et al. Traditional and new methods of bone age assessment-an overview. J Clin Res Pediatr Endocrinol. 2021; 13(3): 251 - 262.

106. Bull R.K., Edwards P.D., Kemp P.M., et al. Bone age assessment: a large scale comparison of the Greulich and Pyle, and Tanner and Whitehouse (TW2) methods. Arch Dis Child. 1999; 81(2): 172 - 173.

107. Alba P., Tsai S., Mitre N. The severity of growth hormone deficiency does not predict the presence or absence of brain magnetic resonance imaging abnormalities - a retrospective review. Eur Endocrinol. 2020 Apr; 16(1): 60 - 64.

108. Hwang J., Jo S.W., Kwon E.B., et al. Prevalence of brain MRI findings in children with nonacquired growth hormone deficiency: a systematic review and meta-analysis. Neuroradiology. 2021; 63(7): 1121 - 1133.

109. Sharma H., Purwar N., Kumar A., et al. Pituitary hypoplasia is the best MRI predictor of the severity and type of growth hormone deficiency in children with congenital growth hormone deficiency. J Pediatr Endocrinol Metab. 2021; 34(7): 851 - 858.

110. Jagtap V.S., Acharya S.V., Sarathi V., et al. Ectopic posterior pituitary and stalk abnormality predicts severity and coexisting hormone deficiencies in patients with congenital growth hormone deficiency. Pituitary. 2012; 15(2): 243 - 250.

111. Root A.W., Dana K., Lippe B. Treatment of growth hormone-deficient infants with recombinant human growth hormone to near adult height: patterns of growth. Horm Res Paediatr. 2011; 75(4): 276 - 283.

112. Reiter E.O., Price D.A., Wilton P., et al. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab. 2006; 91(6): 2047 - 2054.

113. Carel J.C. Adult height after long-term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry. BMJ. 2002; 325(7355): 70.

114. Radetti G., Buzi F., Paganini C., et al. Treatment of GH-deficien children with two different GH doses: effect on final height and cost-benefit implications.Eur J Endocrinol. 2003; 148(5): 515 - 518.

115. Juul A., Bernasconi S., Clayton P.E., et al. European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency. Horm Res. 2002; 58(5): 233 - 241.

116. Sas T.C., De Ridder M.A., Wit J.M., et al. Adult height in children with growth hormone deficiency: a randomized, controlled, growth hormone dose-response trial. Horm Res Paediatr. 2010; 74(3): 172 - 181.

117. Kristrom B., Aronson A.S., Dahlgren J., et al. Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. J Clin Endocrinol Metab. 2009; 94(2): 483 - 490.

118. Дедов И.И., Петеркова В.А., Ширяева Т.Ю., Нагаева Е.В., Волеводз Н.Н., Малиевский О.А., Свинарев М.Ю. Эффективность и безопасность применения растворимой формы препарата Растан у детей с дефицитом гормона роста. Проблемы эндокринологии. 2011: 57(5); 30 - 37.

119. Nagaeva E., Shiryaeva T., Peterkova V., Chikulaeva O., Bezlepkina O. Final height after long-term growth hormone treatment of short children with GH-deficiency, SGA and Turner syndrome. Horm Res in Paediatr. 2013; 80 (suppl 1): 259.

120. L., Cooke R., Tidblad A., et al. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study. Lancet Diabetes Endocrinol. 2020; 8(8): 683 - 692.

121. Losa M., Castellino L., Pagnano A., et al. Growth hormone therapy does not increase the risk of craniopharyngioma and nonfunctioning pituitary adenoma recurrence. J Clin Endocrinol Metab. 2020; 105(5): dgaa089cc.

122. Lutski M., Zucker I., Zadik Z., et al. Prevalence of diabetes among children treated with growth hormone in Israel. Diabet Med. 2019; 36(10): 1276 - 1281.

123. Bell J., Parker K.l., Swinford Rd., et al. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010; 95(1): 167 - 177.

124. Darendeliler F., Karagiannis G., Wilton P. Headache, idiopathic in tracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS Data base. Horm Res. 2007; 68(Supp15): 41 - 47.

125. Malozowski S., Tanner L.A., Wysowski D.K., et al. Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J Pediatr. 1995; 126(6): 996 - 999.

126. Mostoufi-Moab S., Isaacoff E.J., Spiegel D., et al. Childhood cancer survivors exposed to total body irradiation are at significant risk for slipped capital femoral epiphysis during recombinant growth hormone therapy. Pediatr Blood Cancer. 2013; 60(11): 1766 - 1771.

127. Vedi A., Neville K., Johnston K., et al. Slipped capital femoral epiphyses after total body irradiation. Pediatr Blood Cancer. 2014; 61(6): 1140.

128. Carel J.C., Ecosse E., Landier F., et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE Study. J Clin Endocrinol Metab. 2012; 97(2): 416 - 425.

129. Savendahl L., Maes M., Albertsson-Wikland K., et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE Study. J Clin Endocrinol Metab. 2012; 97(2): E213 - 2E17.

130. Wilton P., Mattsson A.F., Darendeliler F. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). J Pediatr. 2010; 157(2): 265 - 270.

131. Albertsson-Wikland K., Martensson A., Savendahl L., et al. Mortality is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics. J Clin Endocrinol Metab. 2016; 101(5): 2149 - 2159.

132. Sklar C.A., Mertens A.C., Mitby P., et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. J Clin Endocrinol Metab. 2002; 87(7): 3136 - 3141.

133. Karavitaki N., Warner J.T., Marland A., et al. GH replacement does not increase the risk of recurrence in patients with craniopharyn gioma. Clin Endocrinol (Oxf). 2006; 64(5): 556 - 560.

134. Raman S., Grimberg A., Waguespack S.G., et al. Risk of neoplasia in pediatric patients receiving growth hormone therapy - a report from the pediatric tndocrine society drug and therapeutics committee. J Clin Endocrinol Metab. 2015; 100(6): 2192 - 2203.

135. Mauras N., Attie K.M., Reiter E.O., et al. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab. 2000; 85(10): 3653 - 3660.

136. Bertelloni S., Baroncelli G.I., Piernicola Garofalo P., et al. Androgen therapy in hypogonadal adolescent males. Hormone Research in Paediatrics. 2010; 74(4): 292 - 296.

137. Mason K.A., Schoelwer M.J., Rogol A.D. Androgens during infancy, childhood, and adolescence: physiology and use in clinical practice. Endocrine Reviews. 2020; 41(3): 421 - 456.

138. Stancampiano M.R., Lucas-Herald A.K., Gianni Russo G., et al. Testosterone therapy in adolescent boys: the need for a structured approach. Horm Res in Paediatr. 2019; 92(4): 215 - 228.

139. Vogiatzi M., Tursi J.P., Jonathan S Jaffe J.S., et al. Testosterone use in adolescent males: current practice and unmet needs. J Endocrine Society. 2020; 5(1): bvaa161.

140. Bhasin S., Brito J.P., Cunningham G.R., et al. Testosterone therapy in men with hypogonadism: An endocrine society clinical practice guideline. Journal Clin Endocrinol Metab. 2018; 103(5): 1715 - 1744.

141. Coviello A.D., Kaplan B., Lakshman K.M., et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. Journal Clin Endocrinol and Metab. 2008; 93(3): 914 - 919.

142. Ankarberg-Lindgren C. [и др.]. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. Journal Clin Endocrinol and Metab. 2001; 7: 86: 3039 - 3044.

143. Norjavaara E., Ankarberg-Lindgren C., B. Sex steroid replacement therapy in female hypogonadism from childhood to young adulthood. Endocrine Development. 2016; 29: 198 - 213.

144. E. Bertelli, M. DI. Frenna, M. Cappa, et al. Hypogonadism in male and female: which is the best treatment? Minerva Pediatr (Torino). 2021; 73(6): 572 - 587.

145. Boulware S.D., Caprio S., et al. Decreased insulin sensitivity and compensatory hyperinsulinemia after hormone treatment in children with short stature. J Clin Endocrinol Metab. 1997; 82(10): 3234 - 3238.

146. Bareille P., Azcona C., Matthews D.R., et al. Lipid profile, glucose tolerance and insulin sensitivity after more than four years of growth hormone therapy in non-growth hormone deficient adolescents. Clin Endocrinol (Oxf). 1999; 51(3): 347 - 353.

147. Cohen P., Bright G.M., Rogol A.D., et al. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab. 2002; 87(1): 90 - 98.

148. Burgers A.M., Biermasz N.R., Schoones J.W., et al. Metaanalysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. J Clin Endocrinol Metab. 2011; 96(9): 2912 - 2920.

149. Cutfield W.S., Wilton P., Bennmarker H., et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet. 2000; 355(9204): 610 - 613.

150. Klein K.O., Phillips S.A. Review of hormone replacement therapy in girls and adolescents with hypogonadism. J Pediatr Adolesc Gynecol. 2019; 32(5): 460 - 468.

151. Стребкова Н.А. Федеральные клинические рекомендации по диагностике и лечению несахарного диабета у детей и подростков//Проблемы Эндокринологии. - 2014. - Т. 60. - N 1. - С. 64 - 69.

152. Approach to the Pediatric Patient: Central Diabetes Insipidus/Giuseppa Patti, Flavia Napoli [и др.]//The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 5, May 2022, Pages 1407 - 1416.

153. Congenital hypogonadotropic hypogonadism, functional hypogonadotropism or constitutional delay of growth and puberty? An analysis of a large patient series from a single tertiary center/T. Varimo, P. J. Miettinen, J. Kansakoski [и др.]//Human Reproduction (Oxford, England). - 2017. - Т. 32. - Congenital hypogonadotropic hypogonadism, functional hypogonado-tropism or constitutional delay of growth and puberty? - N 1. - С. 147 - 153.

154. Predictive value of luteinizing hormone releasing hormone (LHRH) bolus testing before and after 36-hour pulsatile LHRH administration in the differential diagnosis of constitutional delay of puberty and male hypogonadotropic hypogonadism/A. G. Smals, A. R. Hermus, G. H. Boers [и др.]//The Journal of Clinical Endocrinology and Metabolism. - 1994. - Т. 78. - N 3. - С. 602 - 608.

155. Boehm U. и др. European Consensus Statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment//Nat. Rev. Endocrinol. Nature Publishing Group, 2015. Т. 11, N 9. С. 547 - 564.

156. Mason K. A., Schoelwer M. J., Rogol A. D. Androgens During Infancy, Childhood, and Adolescence: Physiology and Use in Clinical Practice//Endocr. Rev. 2020. Т. 41, N 3. С. 421 - 456.

157. Young J. и др. Clinical Management of Congenital Hypogonadotropic Hypogonadism//Endocr. Rev. 2019. Т. 40, N 2. С. 669 - 710.

158. Dunkel L., Quinton R. Transition in Endocrinology: Induction of puberty//Eur. J. Endocrinol. 2014. Т. 170, N 6. С. R229-R239.

159. Rogol A. D. и др. A multicenter, open-label, observational study of testosterone gel (1%) in the treatment of adolescent boys with klinefelter syndrome or anorchia//J. Adolesc. Health Off. Publ. Soc. Adolesc. Med. 2014. Т. 54, N 1. С. 20 - 25.

160. Contreras M. F. и др. Transdermal testosterone gel for induction and continuation of puberty in adolescent boys with hepatic dysfunction//J. Pediatr. Endocrinol. Metab. JPEM. 2017. Т. 30, N 1. С. 105 - 109.

161. Swee D. S., Quinton R. Managing congenital hypogonadotrophic hypogonadism: a contemporary approach directed at optimizing fertility and long-term outcomes in males//Ther. Adv. Endocrinol. Metab. 2019. Т. 10. С. 2042018819826889.

162. Stancampiano M. R. и др. Testosterone Therapy in Adolescent Boys: The Need for a Structured Approach//Horm. Res. Paediatr. Karger Publishers, 2019. Т. 92, N 4. С. 215 - 228.

163. Vogiatzi M. и др. Testosterone Use in Adolescent Males: Current Practice and Unmet Needs//J. Endocr. Soc. 2020. Т. 5, N 1.

164. Barrio R. и др. Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism//Fertil. Steril. Elsevier, 1999. Т. 71, N 2. С. 244 - 248.

165. Rohayem J. и др. Testicular growth and spermatogenesis: new goals for pubertal hormone replacement in boys with hypogonadotropic hypogonadism? -a multicentre prospective study of hCG/rFSH treatment outcomes during adolescence//Clin. Endocrinol. (Oxf.). 2017. Т. 86, N 1. С. 75 - 87

166. Zacharin M. Pubertal induction in hypogonadism: Current approaches including use of gonadotrophins//Best Pract. Res. Clin. Endocrinol. Metab. 2015. Т. 29, N 3. С. 367 - 383.

167. M Z. и др. Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth and may promote early spermatogenesis//Fertil. Steril. Fertil Steril, 2012. Т. 98, N 4.

168. Cangiano B. и др. Predictors of reproductive and non-reproductive outcomes of gonadotropin mediated pubertal induction in male patients with congenital hypogonadotropic hypogonadism (CHH)//J. Endocrinol. Invest. 2021. Т. 44, N 11. С. 2445 - 2454.

169. Testicular growth and spermatogenesis: new goals for pubertal hormone replacement in boys with hypogonadotropic hypogonadism? -a multicentre prospective study of hCG/rFSH treatment outcomes during adolescence/J. Rohayem, B. P. Hauffa, M. Zacharin [и др.]//Clinical Endocrinology. - 2017. - Т. 86. - Testicular growth and spermatogenesis. - N 1. - С. 75 - 87.

170. Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth and may promote early spermatogenesis/Z. M, S. Ma, N. Vv, D. P. - Text: electronic//Fertility and sterility. - 2012. - Vol. 98. - N 4. - URL: https://pub-med.ncbi.nlm.nih.gov/22763096/ (date accessed: 13.11.2023)

171. Predictors of reproductive and non-reproductive outcomes of gonadotropin mediated pubertal induction in male patients with congenital hypogonadotropic hypogonadism (CHH)/Cangiano, G. Goggi, S. Federici [и др.]//Journal of Endocrinological Investigation. - 2021. - Т. 44. - N 11. - С. 2445 - 2454.

172. Ankarberg-Lindgren C. и др. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls//J. Clin. Endocrinol. Metab. 2001. Т. 86, N 7. С. 3039 - 3044.

173. K. Voutsadaki, M. Matalliotakis, и F. Ladomenou, "Hypogonadism in adolescent girls: treatment and long-term effects", Acta Bio-Medica Atenei Parm., т. 93, вып. 5, с. e2022317, окт. 2022, doi: 10.23750/abm.v93i5.13719.

174. Klein K. O., Phillips S. A. Review of Hormone Replacement Therapy in Girls and Adolescents with Hypogonadism//J. Pediatr. Adolesc. Gynecol. 2019. Т. 32, N 5. С. 460 - 468.

175. Bertelloni S., Dati E., Baroncelli G. I. Disorders of sex development: hormonal management in adolescence//Gynecol. Endocrinol. Off. J. Int. Soc. Gynecol. Endocrinol. 2008. Т. 24, N 6. С. 339 - 346.

176. Справочник детского эндокринолога", 3-е издание, И.И. Дедов, В.А. Петеркова Москва, Издательство, "Литерра", 2020, 496 стр.

177. Практическая эндокринология: методы обследования, лабораторные тесты и функциональные пробы: учебное пособие. Главные редакторы: И.И. Дедов, Н.Г. Мокрышева, 2023, Москва, ФГБУ "НМИЦ эндокринологии" Минздрава России, 96 стр.